Elevara Medicines is a London-based biotech company developing innovative therapies for rheumatoid arthritis (RA) and other chronic inflammatory diseases by targeting fibroblast-like synoviocytes rather than just immune cells. Founded to address the unmet needs of RA patients who don’t respond fully to existing immunosuppressive treatments, the company’s lead molecule, ELV001, is a once-daily oral CDK4/6 inhibitor designed to work alongside current disease-modifying therapies rather than replace them. Elevara positions itself to shift the standard of care away from repeated “switching” of treatments by offering a complementary, non-immunosuppressive approach aimed at deeper remission. With its recent $70 million Series A funding and exclusive global rights to ELV001, Elevara is now poised to initiate a Phase 2/2b clinical trial, bringing a new paradigm for RA management closer to reality.